Application of umbilical cord stem cell preparation in preparation of medicine for treating osteoarthritis

An umbilical cord stem cell and osteoarthritis technology, applied in the field of biomedicine, can solve problems such as poor effect and unstable effect, and achieve the effect of improving repair function, increasing expression and reducing inflammatory response

Pending Publication Date: 2021-11-19
HANGZHOU S EVANS BIOSCI LTD
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The drugs currently used clinically can only relieve pain, but the effect is not good
With the continuous development of stem cell research, there are many therapeutic drugs in the field of exploring osteoarthritis, but the effect is not stable enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of umbilical cord stem cell preparation in preparation of medicine for treating osteoarthritis
  • Application of umbilical cord stem cell preparation in preparation of medicine for treating osteoarthritis
  • Application of umbilical cord stem cell preparation in preparation of medicine for treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0030] According to the present disclosure, wherein, the preparation method of the umbilical cord mesenchymal stem cells comprises the following steps: cutting the umbilical cord Wharton's jelly into pieces, placing it in a serum-free complete medium for adherent culture, until the degree of cell confluence is 70-90 %, discard the umbilical cord Wharton's jelly fragments and continue to culture; after the culture is over, digest and disperse the centrifuged cells, then centrifuge and inoculate for subculture to obtain umbilical cord mesenchymal stem cells.

[0031] The umbilical cord mesenchymal stem cells are fibroblast-like cells isolated from umbilical cord tissue, express CD73, CD90 and CD105, and do not express CD14, CD19, CD34, CD45 and HLA-DR.

[0032] According to the present disclosure, the conditions of the primary culture include: the culture time is 14-21 days, and the culture temperature is 37°C; on the 7th-21st day of the primary culture, the culture bottle is com...

Embodiment 1

[0045] After cutting the umbilical cord into 1cm pieces, clean the surface with physiological saline containing double antibodies, and clean up the blood in the tissue; use sterile forceps to peel off the venous tube and arterial tube in the tissue, and the separated jelly is Wharton's gum. Take 1 / 3-2 / 3 of Wharton's jelly for the isolation of umbilical cord stem cells.

[0046] Preparation of umbilical cord mesenchymal stem cell preparation UCMSC: Suspend umbilical cord mesenchymal stem cells in normal saline to prepare umbilical cord stem cell suspension, the total volume is 50 μL, and the concentration of umbilical cord mesenchymal stem cells is 2×10 6 individual / mL.

[0047] Rat osteoarthritis model construction: Inject 100 μL of 25 mg / mL iodoacetic acid into the knee joint cavity of rats with a syringe to induce early knee osteoarthritis in rats, and the model construction was completed one week later.

[0048] Inject the above-mentioned umbilical cord mesenchymal stem c...

Embodiment 2

[0050] The preparation of umbilical cord mesenchymal stem cells and the construction process of the rat model in this example are the same as those in Example 1.

[0051]Preparation of tissue extract: Take the remaining part of Wharton's jelly from Example 1 and mix it with normal saline 1 at a volume ratio of 1:5, and use a tissue homogenizer to break the tissue; centrifuge the broken tissue at 3000rpm for 10 minutes, and take the The supernatant was centrifuged three times under these conditions; after centrifugation at 10,000 rpm for 30 min, the supernatant was taken and filtered with a 0.22 μm filter, and the obtained liquid was Wharton's jelly tissue lysate. Then, the tissue lysate was centrifuged at 4°C and 4000g for 20 minutes using a 10KD ultrafiltration tube to obtain tissue extract 1 with a molecular weight greater than 10KD; After the filter tube was centrifuged at 4°C and 4000g for 20 minutes, the obtained concentrate was a protein with a molecular weight of 3-10KD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of an umbilical cord stem cell preparation in preparation of a medicine for treating osteoarthritis. The umbilical cord stem cell preparation comprises umbilical cord mesenchymal stem cells, a tissue extracting solution and isoliquiritigenin. The umbilical cord stem cells can reduce inflammatory response and improve expression of cartilage cell marker genes to a certain extent, the tissue extracting solution is added, and the isoliquiritigenin and the umbilical cord stem cells are mixed for use, so that the repair function of the umbilical cord stem cells can be effectively improved, and the efficacy of the umbilical cord stem cells for treating osteoarthritis is exerted.

Description

technical field [0001] The present disclosure relates to the technical field of biomedicine, in particular to the application of an umbilical cord stem cell preparation in the preparation of a drug for treating osteoarthritis. Background technique [0002] Arthritis is a type of chronic arthritic disease with joint degeneration or aging as the pathological basis and joint swelling, pain or dysfunction as the main clinical manifestations. It was formerly known as osteoarthritis, degenerative osteoarthritis or hypertrophic joint Inflammation, collectively referred to as osteoarthritis. Osteoarthritis tends to occur in middle-aged and elderly people, obese patients, sports enthusiasts or some professional athletes. With the improvement of living conditions and the development of society, the incidence of osteoarthritis is increasing year by year. It is known that more than 70% of the elderly are suffering from various joint pains, and osteoarthritis is the most common arthrit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/51A61P19/02A61P29/00C12N5/0775A61K31/122A61K35/28
CPCA61K35/51A61K35/28A61K31/122A61P19/02A61P29/00C12N5/0668C12N2509/00A61K2300/00Y02A50/30
Inventor 潘若浪张强潘欣张玲戴玲华
Owner HANGZHOU S EVANS BIOSCI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap